Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more
Vineet Laboratories Limited (VINEETLAB) - Total Liabilities
Latest total liabilities as of September 2025: ₹764.24 Million INR
Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has total liabilities worth ₹764.24 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vineet Laboratories Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Vineet Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vineet Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Vineet Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Recrusul S/A
SA:RCSL3
|
Brazil | R$65.75 Million |
|
Transwarranty Finance Limited
NSE:TFL
|
India | ₹523.85 Million |
|
Inomin Mines Inc
V:MINE
|
Canada | CA$1.56 Million |
|
Kardan Israel Ltd
TA:KRDI
|
Israel | ILA1.83 Billion |
|
Prospech Ltd
AU:PRS
|
Australia | AU$864.39K |
|
Meihua International Medical Technologies Co Ltd
NASDAQ:MHUA
|
USA | $25.64 Million |
|
GENMAB (GE9.SG)
STU:GE9
|
Germany | €7.74 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Vineet Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vineet Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vineet Laboratories Limited (2017–2025)
The table below shows the annual total liabilities of Vineet Laboratories Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹798.92 Million | -2.75% |
| 2024-03-31 | ₹821.48 Million | -0.02% |
| 2023-03-31 | ₹821.66 Million | -18.17% |
| 2022-03-31 | ₹1.00 Billion | +22.27% |
| 2021-03-31 | ₹821.26 Million | +20531525.00% |
| 2020-03-31 | ₹4.00K | -94.65% |
| 2019-03-31 | ₹74.78K | -35.80% |
| 2018-03-31 | ₹116.48K | +1064.80% |
| 2017-03-31 | ₹10.00K | -- |